Quick Answer
Protalix BioTherapeutics, Inc. reported Total Assets of $82.35 million for the year ending 2025.
- Protalix BioTherapeutics, Inc. showed an increase of +12.2% in Total Assets from 2024 to 2025.
- This data is from Protalix BioTherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2011: $71.89 million | Q3 2011: $60.83 million | Q1 2012: $68.46 million | Q2 2012: $84.30 million | Q3 2012: $77.38 million | Q1 2013: $69.94 million | Q2 2013: $62.31 million | Q3 2013: $121.16 million | Q1 2014: $103.42 million | Q2 2014: $96.65 million | Q3 2014: $84.80 million | Q1 2015: $72.05 million | Q2 2015: $65.95 million | Q3 2015: $59.49 million | Q1 2016: $87.31 million | Q2 2016: $78.86 million | Q3 2016: $70.47 million | Q1 2017: $71.85 million | Q2 2017: $59.00 million | Q3 2017: $61.06 million | Q1 2018: $64.80 million | Q2 2018: $51.72 million | Q3 2018: $67.20 million | Q1 2019: $61.04 million | Q2 2019: $55.24 million | Q3 2019: $53.73 million | Q1 2020: $82.88 million | Q2 2020: $71.71 million | Q3 2020: $72.31 million | Q1 2021: $102.79 million | Q2 2021: $108.20 million | Q3 2021: $83.48 million | Q1 2022: $68.39 million | Q2 2022: $60.64 million | Q3 2022: $56.71 million | Q1 2023: $66.56 million | Q2 2023: $88.42 million | Q3 2023: $87.57 million | Q1 2024: $89.83 million | Q2 2024: $91.54 million | Q3 2024: $61.56 million | Q1 2025: $73.89 million | Q2 2025: $78.49 million | Q3 2025: $82.26 million.
- Over the full 16 years of available data (2010 to 2025), Protalix BioTherapeutics, Inc.'s Total Assets has grown by 27.2%.
- Historical annual values: Fiscal year 2025: $82.35 million | Fiscal year 2024: $73.42 million | Fiscal year 2023: $84.43 million | Fiscal year 2022: $55.79 million | Fiscal year 2021: $73.67 million | Fiscal year 2020: $67.93 million | Fiscal year 2019: $45.39 million | Fiscal year 2018: $61.13 million | Fiscal year 2017: $72.21 million | Fiscal year 2016: $82.25 million | Fiscal year 2015: $97.25 million | Fiscal year 2014: $78.36 million | Fiscal year 2013: $113.33 million | Fiscal year 2012: $78.73 million | Fiscal year 2011: $51.81 million | Fiscal year 2010: $64.73 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: